Group 1 - CRISPR Therapeutics AG closed at $38.54, reflecting a -1.76% change from the previous day, underperforming compared to the S&P 500's gain of 1.67% [1] - The company has experienced a 4.06% decline in share price over the past month, while the Medical sector and S&P 500 have lost 9.34% and 6.57%, respectively [1] Group 2 - Analysts expect CRISPR Therapeutics AG to report earnings of -$1.27 per share, indicating a year-over-year growth of 11.19%, with revenue projected at $5.24 million, a significant increase of 947.2% compared to the same quarter last year [2] - For the full year, earnings are anticipated to be -$5.09 per share and revenue at $56.98 million, reflecting changes of -17.28% and +52.69% from the previous year [3] Group 3 - Recent changes to analyst estimates for CRISPR Therapeutics AG are important as they reflect the company's business dynamics and potential profitability [4] - The Zacks Rank system, which evaluates estimate changes, indicates that CRISPR Therapeutics AG currently holds a Zacks Rank of 3 (Hold) [6] Group 4 - The Medical - Biomedical and Genetics industry, which includes CRISPR Therapeutics AG, is ranked 77 in the Zacks Industry Rank, placing it in the top 32% of over 250 industries [7] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1, indicating a favorable environment for companies within this industry [7]

Core Insights - The biotech industry presents opportunities for significant returns in short timeframes due to clinical or regulatory advancements, with several companies projected to see substantial share price increases in the next year [1][2] Group 1: CRISPR Therapeutics - CRISPR Therapeutics is a leading gene-editing company that received approval for its therapy Casgevy, the first CRISPR-based medicine, but has struggled with sales post-approval due to complex administration [3][4] - Wall Street's average price target for CRISPR Therapeutics is $84.62, indicating a potential upside of 159%, making it a long-term investment consideration despite short-term volatility [4][5] - The company has a promising pipeline, including potential treatments for type 1 diabetes and cancer, appealing to risk-tolerant investors [5] Group 2: Iovance Biotherapeutics - Iovance Biotherapeutics specializes in cancer therapies using tumor-infiltrating lymphocytes and gained U.S. approval for Amtagvi to treat melanoma, achieving $164.1 million in revenue in 2024 [6][7] - The stock has a price target of $20.91, suggesting a potential upside of 543%, with upcoming regulatory approvals and a large patient base in the U.S. as catalysts for growth [7][8] - Iovance could be an attractive option for patient investors, given its innovative approach and potential for further clinical successes [9] Group 3: Regeneron - Regeneron is a well-established biotech firm facing challenges with its key product Eylea due to competition, but has a price target of $914.55, indicating a 50% upside [10] - A legal battle over Eylea's biosimilar could significantly impact share prices, while the success of Dupixent and a robust pipeline enhance its investment appeal [11][12] - The company has initiated a dividend program and continues share buybacks, reinforcing its position as a strong long-term investment [12] Group 4: Sarepta Therapeutics - Sarepta Therapeutics focuses on gene therapies for rare diseases and recently launched Elevidys, but faced a setback with a patient death linked to liver failure [13][14] - Despite the controversy, the average price target remains at $165.35, suggesting an upside of 182%, contingent on clarifying the cause of the patient's death [14][15] - Given the current uncertainty surrounding Elevidys, caution is advised for potential investors until more information is available [15]

ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at ...

A bad combination compounding for biotech So not only were these stocks slammed by the risk-off mentality in the markets ahead of tariffs coming on April 2, but a key resignation at the Federal Drug Administration (FDA) over the weekend raised questions about the speed and willingness of the agency to approve new drug technologies going forward. The double whammy sent these stocks down much more than the market today. Key FDA regulator Marks abruptly leaves Over the weekend, Dr. Peter Marks, who headed the ...

Genomics encompasses the study of a complete set of genes, their work process, and their way of interacting with each other and the environment. While it incorporates elements of genetics, the primary focus is on characterizing all the genes of an organism, rather than individual genes.The evolution of genomics in the last couple of decades to decode diseases has ushered in a revolutionary era in genetic medicine. There have been several breakthroughs in this field, attracting the attention of pharma and bi ...

ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025. "Julie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfull ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CRSP over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking ...

Group 1: CRISPR Therapeutics - CRISPR Therapeutics' shares have declined by 41% over the past year, primarily due to slow revenue generation from its approved gene-editing therapy, Casgevy, which treats rare blood diseases [2][3] - Casgevy is priced at $2.2 million per treatment and is a one-time curative option, with a significant market opportunity in the U.S., U.K., European Union, and several Middle Eastern countries [5][4] - The company is also developing other gene-editing therapies, including a functional cure for type 1 diabetes and CTX112 for B-cell malignancies, which has received Regenerative Medicine Advanced Therapy designation [6][7] Group 2: Merck - Merck's revenue for the last year was $64.2 billion, a 7% increase from 2023, with Keytruda generating $29.5 billion, accounting for approximately 46% of total revenue [9][12] - Competition from ivonescimab, which performed better than Keytruda in a clinical trial, poses a risk to Keytruda's market share, especially as its patent will expire in 2028 [8][9] - Merck is proactively extending Keytruda's patent life and developing new medicines, including LM-299 and HS-10535, while maintaining a strong dividend yield of over 3.4% [10][11][12]

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue to gain after that company moves into the product commercialization stage.Once biotech products reach the marketplace, biotech companies benefit just like pharma companies from the following: Patients need their treatments regardless of the general economic ...

Shares of CRISPR Therapeutics (CRSP) closed at $40.97 on Tuesday, close to their 52-week low of $36.52.This decline in CRSP stock is mainly due to a lack of pipeline updates, which is not sitting well with investors. Also, the company is yet to record revenues from the sales of its sole-marketed product Casgevy, despite it being approved in early 2024.Shares of CRISPR Therapeutics have plunged 43% in the past year compared with the industry’s 7% decline, as seen in the chart below. The stock has also underp ...